Magnyl Magnus Pharmaceuticals

How to use Magnyl Magnus Pharmaceuticals

Magnyl Magnus Pharmaceuticals contains gonadotropin. This is a hormone secreted by the placenta during pregnancy. All gonadotropin preparations contain a natural, purified, ready-to-use hormone. It is administered intramuscularly and is used as a maintenance or post-cycle treatment in a course of steroids.

Main effects: Magnyl Magnus Pharmaceuticals

Gonadotropin is useful because it can protect against the side effects caused by steroids. It has these properties:

• it stimulates the production of sex hormones in the testicles;
• prevents testicular atrophy;
• stimulates spermatogenesis;
• enhances the manifestation of secondary sexual characteristics;
• leads to the same effects as testosterone.

It is also used by women to stimulate ovulation and progesterone production

Although the effects of gonadotropin are the same as those of testosterone, it should not be taken to increase muscle mass. This will require very high doses of gonadotropin, and is dangerous to men’s health. It can be taken in conjunction with other low dose steroids, as this will help maintain muscle mass and eliminate some of the side effects of steroids.

Possible negative effects

On its own, gonadotropin is safe. But in high doses, it can suppress testosterone production. Also, if the athlete’s body is sensitive to testosterone, side effects can occur when taking the drug, such as testosterone side effects: gynecomastia, fluid accumulation in the tissues, androgenic manifestations, etc.

Rules of course construction

The best time to take Gonadotropin: the last 3-5 weeks of the course. Up to 500 IU of the drug twice a week is recommended. This protects against testicular atrophy. The drug is necessary for courses that last longer than 6 weeks, contain high doses or 2 or more drugs.

The gonadotropin is cancelled when the steroid is completely eliminated from the body. The athlete then undergoes post cycle therapy.

The plug pattern may differ. Before use, consult your doctor and find out which option is best for you.

List of references

1. Howles CM. Role of gonadotropin-releasing hormone agonists, antagonists, and aromatase inhibitors in controlling follicle-stimulating hormone and luteinizing hormone levels. Clinical Obstetrics and Gynecology. 2015;58(2):257-267.
2. Casarini L, Brigante G, Simoni M. Spermatogenesis and its regulation: an evolutionary overview. Human Reproduction Update. 2017;23(5):560-585.
3. Grøndahl ML, Borup R, Lee YB, Myrhoj V, Meinertz H, Sørensen S. The transcriptome of corona radiata cells from individual MII oocytes that after ICSI developed to embryos selected for transfer: PCOS women compared to healthy women. Human Reproduction. 2010;25(6):1509-1520.
4. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.